Fenfluramine Synthesis via Reductive Amination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing fenfluramine are inefficient due to multiple steps, use of hazardous reagents, and contamination risks, making them unsuitable for industrial production, especially for chronic therapies where metal accumulation is a concern.
Innovation Solution
A new synthesis method involving the transformation of a ketone with ethylamine and a reducing agent like sodium borohydride or sodium triacetoxyborohydride, which avoids heavy metals and transition metals, allowing for a one- or two-step process with high yield and purity, and the option to form a pharmaceutically acceptable salt.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If multiple synthesis steps are used to prepare fenfluramine, then the transformation can be achieved with available reagents, but the overall yield decreases and impurities increase
Solution Approach 1:
The patent combines multiple synthesis steps into a single one-pot reductive amination reaction. The ketone reacts with ethylamine to form an imine intermediate, which is then reduced by borohydride reagents to yield fenfluramine directly, eliminating the need for separate isolation and purification steps for intermediates.
Solution Approach 2:
The reaction conditions are designed so that the imine formation and reduction occur sequentially in the same reaction medium. The ethylamine and ketone first form the imine in situ, and then the borohydride reagent reduces the imine to the amine product without requiring intermediate isolation.
2Ease of manufacture
If multiple synthesis steps are used, then the reaction can proceed through necessary intermediates, but the number of impurities increases and purification becomes more difficult
Solution Approach 1:
By combining imine formation and reduction in a single reaction pot, the patent minimizes the number of isolation steps that could introduce impurities. The continuous reaction environment maintains better control over intermediate species and reduces exposure to contamination.
Solution Approach 2:
The imine intermediate is formed in situ and immediately reduced by the borohydride reagent, preventing its accumulation and potential degradation. This mediated approach ensures that the intermediate is converted to the final product under controlled conditions without requiring isolation.
3Productivity
If hazardous reagents like lithium aluminum hydride are used, then the reduction can be achieved, but safety risks and toxicity increase
Solution Approach 1:
The patent employs borohydride reagents (sodium borohydride, potassium borohydride, or ammonium triacetoxyborohydride) that are less hazardous than lithium aluminum hydride. These reagents are milder, easier to handle, and their byproducts are less toxic, making them suitable for industrial and pharmaceutical applications.
Solution Approach 2:
The patent changes the chemical parameters of the reducing agent from highly reactive lithium aluminum hydride to milder borohydride reagents. This parameter change maintains reduction efficiency while significantly improving safety and reducing toxicity, allowing the reaction to proceed under more benign conditions.
4Productivity
If Raney nickel catalyst is used for oxime reduction, then the reduction can be achieved, but metal contamination of the final product occurs
Solution Approach 1:
The patent replaces the mechanical/catalytic approach using Raney nickel with a chemical reduction approach using borohydride reagents. This substitution eliminates the need for metal catalysts that could contaminate the final product, while still achieving efficient reduction of the imine to amine.
Solution Approach 2:
The borohydride reagents used are non-metallic and do not require filtration or special handling to remove metal contamination. The reduction is achieved through a chemical mechanism that leaves no residual metal catalyst in the final product, ensuring high purity.
5Ease of manufacture
If a long synthesis path with multiple steps is used, then the transformation can be achieved, but the production cost and time increase
Solution Approach 1:
The patent merges the imine formation step and the reduction step into a single operational sequence. Both transformations occur in the same reaction vessel under the same conditions, eliminating the time required for intermediate isolation, solvent removal, and re-setup between steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a safer, more efficient, and cost-effective synthesis of fenfluramine with high purity and reduced impurities, suitable for chronic therapies by eliminating the use of hazardous reagents and metal contamination.
Implementation Method 1
transformation of a ketone having the structure (II) with ethylamine and with a reducing agent chosen from the group consisting of alkali metal cation or ammonium borohydride, alkali metal cation or ammonium triacetoxyborohydride and alkali metal cation or ammonium cyanoborohydride
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A new process for preparing the fenfluramine molecule or isomers thereof and/or analogs thereof and new compositions containing fenfluramine or isomers thereof and/or analogs thereof obtainable with the claimed process.